Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

U.S. Genomics Announces New Chief Executive Officer

Published: Friday, December 16, 2005
Last Updated: Friday, December 16, 2005
Bookmark and Share
John J. Canepa has been promoted to President, CEO and member of the Board of Directors.

U.S. Genomics has announced that John J. Canepa has been promoted to President, Chief Executive Officer and member of the Board of Directors.

"John's business acumen, combined with his extensive experience in the life sciences, represents an unparalleled set of qualifications to lead this company through its commercialization efforts and the next phase of its biodefense contract," said Gus Lawlor, Managing Director at HealthCare Ventures and a U.S. Genomics board member.

"We are excited to move forward in this next phase of biodefense development and commercialization of the single molecule biology technology under John's leadership."

Canepa originally joined U.S. Genomics as Chief Financial Officer. During his tenure as CFO, Canepa saw the Company through the development and launch of the Trilogy® 2020 platform and Direct™ miRNA assays and through two phases of a multi-million-dollar biodefense contract with the U.S. Department of Homeland Security.

Prior to joining U.S. Genomics, Canepa served as Vice President, Finance & Administration, and Chief Financial Officer of Winphoria Networks, Inc., a venture capital-backed telecommunications company.

Previously he was a senior partner in the Boston office of Arthur Andersen, where he led the firm's worldwide life sciences practice.

Canepa holds a Masters in Finance from Michigan State University and a B.A. from Denison University.

"U.S. Genomics has made great strides with its biodefense work and this is an especially exciting time to be part of this company," said Canepa.

"It is a privilege to lead such a dynamic team in both the biodefense applications and the development of the Trilogy 2020 platform and assays."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

U.S. Genomics Announces Recipient of Outstanding Investigator in Single Molecule Biology Award
Dr. James A. Spudich will be presented the award at the 50th Annual Meeting of the Biophysical Society.
Tuesday, February 21, 2006
NSF Awards U.S. Genomics a $500K Phase II-B SBIR Grant
The $500,000 grant is earmarked for development of a commercial platform that uses the Company's rapid DNA analysis and genomic mapping technologies.
Friday, October 07, 2005
U.S. Genomics Expands its Efforts With New VP
U.S. Genomics Names Duncan Whitney as Vice President of Research and Development.
Friday, September 30, 2005
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Mutations in DNA-Repair Genes Found in Advanced Prostate Cancers
New findings indicate that nearly 12% of male advanced prostate cancer sufferers have inherited mutation in DNA-repair genes.
Ice Bucket Challenge Instrumental in Gene Discovery
Donations from the ALS Ice Bucket Chellenge allowed for the largest-ever study of inherited ALS, which identified a new ALS gene.
Triple-Action Therapy Patch Shows Promise
Patch that delivers drug, gene, and light-based therapy to tumor sites shows promising results in mice.
Cancer Gene-Drug Combinations Ripe for Precision Medicine
The study aims to expand the number of cancer gene mutations that can be paired with a precision therapy.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Colon Cancer Blocked in Mice
Case Western Reserve University Researchers block common type of colon cancer tumour in mice, laying groundwork for human clinical trial.
Cancer Related Immune Response Genes Uncovered
Researchers at the SBP have identified over 100 new genetic regions that affect the immune response to cancer.
New Therapeutic Targets For Small Cell Lung Cancer Identified
Researchers at UTSW Medical Center have identified a protein termed ASCL1 that is essential to the development of small cell lung cancer.
Deciphering Inactive X Chromosomes
Untangling the Barr body of inactive X chromosomes valuable for understanding chromosome structure and gene expression.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!